Zacks: Analysts Anticipate SAGE Therapeutics Inc (SAGE) to Announce -$2.40 EPS
Wall Street brokerages expect SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings of ($2.40) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for SAGE Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.68) and the highest estimate coming in at ($2.02). SAGE Therapeutics posted earnings of ($1.97) per share in the same quarter last year, which indicates a negative year over year growth rate of 21.8%. The company is scheduled to announce its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that SAGE Therapeutics will report full year earnings of ($7.37) per share for the current financial year, with EPS estimates ranging from ($9.21) to ($5.24). For the next financial year, analysts forecast that the firm will report earnings of ($10.42) per share, with EPS estimates ranging from ($20.74) to ($5.06). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for SAGE Therapeutics.
SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million during the quarter.
NASDAQ SAGE traded down $3.38 during trading on Monday, hitting $142.63. The company had a trading volume of 349,600 shares, compared to its average volume of 499,493. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97. The firm has a market capitalization of $6.81 billion, a PE ratio of -20.54 and a beta of 2.90.
Several institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of SAGE Therapeutics by 1.6% in the 2nd quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock worth $1,092,169,000 after acquiring an additional 110,687 shares in the last quarter. BlackRock Inc. increased its stake in SAGE Therapeutics by 9.6% during the 1st quarter. BlackRock Inc. now owns 3,774,283 shares of the biopharmaceutical company’s stock valued at $607,923,000 after purchasing an additional 330,112 shares in the last quarter. OppenheimerFunds Inc. increased its stake in SAGE Therapeutics by 2.2% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock valued at $250,162,000 after purchasing an additional 34,389 shares in the last quarter. Bank of New York Mellon Corp increased its stake in SAGE Therapeutics by 7.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock valued at $244,898,000 after purchasing an additional 110,134 shares in the last quarter. Finally, BB Biotech AG increased its stake in SAGE Therapeutics by 6.9% during the 2nd quarter. BB Biotech AG now owns 1,071,373 shares of the biopharmaceutical company’s stock valued at $167,702,000 after purchasing an additional 68,934 shares in the last quarter.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Recommended Story: Asset Allocation Models, Which is Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.